Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 54(2); 2022 > Article
Special Article Prediction of Cancer Incidence and Mortality in Korea, 2022
Kyu-Won Jung1,2orcid, Young-Joo Won1,2,3orcid, Mee Joo Kang1,2, Hyun-Joo Kong1,2, Jeong-Soo Im4, Hong Gwan Seo1,3
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2022;54(2):345-351.
DOI: https://doi.org/10.4143/crt.2022.179
Published online: March 21, 2022

1Korea Central Cancer Registry, National Cancer Center, Goyang, Korea

2Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea

3National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea

4National Cancer Control Institute, National Cancer Center, Goyang, Korea

Correspondence: Young-Joo Won, The Korea Central Cancer Registry, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea,
Tel: 82-31-920-2015, Fax: 82-31-920-2179, E-mail: astra67@ncc.re.kr
• Received: March 18, 2022   • Accepted: March 18, 2022

Copyright © 2022 by the Korean Cancer Association

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 14,226 Views
  • 524 Download
  • 64 Web of Science
  • 55 Crossref
  • 61 Scopus
prev next
Full Article

Download PDF Download PDF

  • Purpose
    This study aimed to report the projected cancer incidence and mortality for the year 2022 to estimate Korea’s current cancer burden.
  • Materials and Methods
    Cancer incidence data from 1999 to 2019 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2020 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against their respective years and then by multiplying the projected age-specific rates by the anticipated age-specific population for 2022. A joinpoint regression model was used to determine the year in which the linear trend changed significantly; we only used the data of the latest trend.
  • Results
    In total, 274,488 new cancer cases and 81,277 cancer deaths are expected to occur in Korea in 2022. The most common cancer site is expected to be the thyroid, followed by the lung, colon and rectum, breast, and stomach. These five cancers are expected to represent half of the overall burden of cancer in Korea. The most common type of cancer leading to death is expected to be lung cancer, followed by liver, colorectal, pancreatic, and gallbladder cancers.
  • Conclusion
    The incidence rates for all types of cancer in Korea are estimated to gradually decrease. These up-to-date estimates of the cancer burden in Korea could be an important resource for planning and evaluating cancer-control programs.
  • Key words: Incidence, Mortality, Neoplasms, Forecasting, Korea, 2022
As the leading cause of death in Korea [1], cancer has been a major public health concern in the country since 1983. More than 240,000 patients were newly diagnosed with cancer in Korea, and one-fourth of deaths were due to cancer in 2018 [2]. Although the cancer registration system in Korea is highly efficient and can provide nationwide cancer statistics within a relatively short period, a lag time of at least 2 years is required to collect and analyze data for a specific year. For planning and implementing comprehensive cancer-control programs, it is important to assess the number of new cases and deaths that are expected to occur during the current year. In this study, we report the projected cancer incidence and mortality for the year 2022 based on data from the 1990s to 2019.
The Korean Ministry of Health and Welfare initiated a nationwide, hospital-based cancer registry, known as the Korea Central Cancer Registry (KCCR), in 1980. The history, objectives, and activities of the KCCR have been documented in detail elsewhere [3]. Cancer incidence data from 1999 to 2019 were obtained from the Korea National Cancer Incidence Database (KNCI DB). Cancer cases were classified according to the International Classification of Diseases for Oncology, 3rd edition [4] and converted according to the International Classification of Diseases, 10th edition (ICD-10) [5]. Mortality data from 1993 to 2020 were acquired from Statistics Korea [1]. The cause of death was coded and classified according to the ICD-10 [5].
The cancer sites included in this study were (1) all cancer sites combined and (2) the 24 cancer sites as follows: lips, oral cavity, and pharynx (C00–C14), esophagus (C15), stomach (C16), colon and rectum (C18–C20), liver (C22), gallbladder etc. (C23–C24), pancreas (C25), larynx (C32), lung (C33–C34), breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), testis (C62), kidney (C64), bladder (C67), brain and central nervous system (C70–C72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82–C86, C96), multiple myeloma (C90), leukemia (C91–C95), and other and ill-defined sites (remainder of C00–C96).
The population data from 1993 to 2022 were obtained from the resident registration population data, reported by Statistics Korea. Data of the mid-year population (July 1 of the respective year) were used as the denominator to obtain the annual incidence and mortality rates. However, for the year 2022, we used the population data on December 31, 2020, as the mid-2022 resident registration population data were not yet available at the time of the analysis.
Linear regression models [6] were used to assess time trends and create projections. We first performed a joinpoint regression analysis on the data available to detect the year when significant changes occurred in cancer trends according to sex and cancer site. A joinpoint regression describes changes in data trends by connecting several different line segments on a log scale at “joinpoints.” This analysis was performed using Joinpoint software (Version 4.7.0.0; http://surveillance.cancer.gov/joinpoint) from the Surveillance Research Program of the US National Cancer Institute [7]. For the analysis, we arranged to have at least four data points between consecutive joinpoints. Secondly, to predict age-specific cancer rates, a linear regression model was fitted to age-specific rates by 5-year age groups against their respective years, based on the observed cancer incidence data of the latest trends. Finally, we multiplied the projected age-specific rates by the age-specific population to get the projected number of cancer cases and deaths for the year 2022.
We summarized the results using crude rates (CRs) and age-standardized rates (ASRs) of cancer incidence and mortality. ASRs were standardized using the world standard population [8] and expressed per 100,000 persons.
1. Incidence
In total, 274,488 new cancer cases are expected to occur in 2022 (Table 1, Fig. 1); more men (n=144,487) than women (n=130,001) are expected to be affected.
The projected CRs per 100,000 for all of the sites combined in 2022 are 561.2 cases and 502.1 cases for men and women, respectively (Table 2). The projected ASRs per 100,000 for all of the sites combined are 289.9 cases and 276.1 cases for men and women, respectively. In men, the five leading primary sites of cancer are expected to be the prostate (CR, 87.0; ASR, 40.3), lung (CR, 84.8; ASR, 39.4), stomach (CR, 68.3; ASR, 34.0), colon and rectum (CR, 66.8; ASR, 33.8) and liver (CR, 41.9; ASR, 20.9), accounting for 62.1% of all new cancer cases in 2022. In women, the five leading primary sites are expected to be the breast (CR, 108.3; ASR, 66.1), thyroid (CR, 96.3; ASR, 71.2), colon and rectum (CR, 46.3; ASR, 19.8), lung (CR, 44.3; ASR, 18.6), and stomach (CR, 34.1; ASR, 15.3), accounting for 65.6% of all new cancer cases in 2022 (Fig. 1).
The five most common cancer sites expected in 2022 according to sex and age group are shown in Table 3. Leukemia and thyroid cancer are expected to be the most common forms of cancer in both sexes for those aged 0–14 years and 15–34 years, respectively. Colorectal cancer is predicted to be the most prevalent cancer in men aged 35–64 years, while prostate cancer is expected to be more frequent in men aged 65 years and above. Breast cancer is predicted to be the most common cancer in women aged 35–64 years, whereas lung cancer is expected to be the most common form in women aged 65 years and above. According to the projection, the incidences of stomach, lung, liver, colorectal, and prostate cancers will increase gradually with age for men (Fig. 2A). In women, the age-specific incidence rates for stomach, colorectal, liver, lung, and cervical cancers denote an increasing trend with age; however, the incidences of breast and thyroid cancers in women are expected to level off after the age of 45 and 50 years, respectively (Fig. 2B).
2. Mortality
It is estimated that 81,277 cancer deaths will occur in Korea during 2022 (Table 1, Fig. 1). The projected CRs per 100,000 for all of the sites combined in 2022 for men and women are 192.8 cases and 122.2 cases, respectively, whereas the projected ASRs per 100,000 for all sites combined for men and women are expected to be 89.1 cases and 44.0 cases, respectively (Table 4). The predicted five leading cancer sites causing mortality in men are the lung (CR, 52.9; ASR, 23.4), liver (CR, 27.2; ASR, 13.0), colon and rectum (CR, 18.9; ASR, 8.8), pancreas (CR, 14.5; ASR, 6.8), and stomach (CR, 13.9; ASR, 6.5). During the same period, lung cancer (CR, 18.2; ASR, 5.9) is projected to be the leading cause of cancer death in women, followed by colon and rectal (CR, 15.1; ASR, 4.7), pancreatic (CR, 13.7; ASR, 4.6), breast (CR, 11.2; ASR, 5.7), and liver (CR, 9.9; ASR, 3.2) cancers.
The predicted age-specific mortality rates of the leading causes of cancer-associated death in men and women in 2022 are shown in detail in Fig. 3. According to age, Korean men and women aged at least 60 years are expected to have the highest mortality rates due to lung cancer.
A total of 274,488 new cancer cases and 81,277 cancer deaths are expected to occur in Korea during 2022. Prostate cancer is predicted to be the most common type of cancer among men, followed by lung, stomach, colorectal, and liver cancers. Lung, liver, colorectal, pancreatic, and stomach cancers are expected to be the most common causes of cancer deaths among men. In women, the five leading primary cancer sites are expected to be the breast, thyroid, colon and rectum, lung, and stomach, while lung, colorectal, pancreatic, breast, and liver cancers are projected to be the most common causes of cancer deaths.
Cancer is currently one of the foremost public health concerns in Korea. Although cancer incidence rates are anticipated to slightly decrease, the burden of most types of cancers will continue to grow with the increasing age of the population. The current projections of cancer incidence and mortality for 2022 represent an important resource for planning and evaluating cancer-control programs. As the estimates in this study are model-based, these results should be interpreted with caution.
Acknowledgements
The authors would like to thank the tumor registrars (health information managers) of the KCCR-affiliated hospitals and non-KCCR-affiliated hospitals for the assistance with data collection, abstraction, and coding. Additionally, we acknowledge the cooperation of the National Health Insurance Service and Statistics Korea for their support with the data.
This work was supported by the National Cancer Center research grant (No. 2211110).

Author Contributions

Conceived and designed the analysis: Won YJ.

Contributed data or analysis tools: Jung KW, Won YJ, Kong HJ.

Performed the analysis: Jung KW.

Wrote the paper: Jung KW, Won YJ.

Interpretation and review: Kang MJ.

Review and comment: Im JS, Seo HG.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Fig. 1
The 10 leading types of estimated new cancer cases and deaths by sex in 2022. (A) Estimated new cases. (B) Estimated deaths.
crt-2022-179f1.jpg
Fig. 2
Projected age-specific incidences of major cancers during 2022 in Korea. (A) Men. (B) Women.
crt-2022-179f2.jpg
Fig. 3
Projected age-specific mortality rates of major cancers during 2022 in Korea. (A) Men. (B). Women.
crt-2022-179f3.jpg
Table 1
Estimated new cancer cases and deaths by sex during 2022 in Korea
Site Estimated new cases Estimated deaths
Both sexes Men Women Both sexes Men Women
All sites 274,488 144,487 130,001 81,277 49,648 31,629
Lip, oral cavity, and pharynx 4,212 3,024 1,188 1,270 922 348
Esophagus 2,742 2,421 321 1,244 1,103 141
Stomach 26,422 17,590 8,832 5,441 3,578 1,863
Colon and rectum 29,165 17,187 11,978 8,790 4,873 3,917
Livera) 14,493 10,782 3,711 9,549 6,994 2,555
Gallbladderb) 8,558 4,606 3,952 5,540 3,017 2,523
Pancreas 9,238 4,756 4,482 7,277 3,730 3,547
Larynx 1,058 999 59 217 217 0
Lungc) 33,294 21,837 11,457 18,320 13,606 4,714
Breast 28,142 110 28,032 2,909 19 2,890
Cervix uteri 2,971 - 2,971 749 - 749
Corpus uteri 3,640 - 3,640 418 - 418
Ovary 3,173 - 3,173 1,392 - 1,392
Prostate 22,391 22,391 - 2,278 2,278 -
Testis 337 337 - 18 18 -
Kidney 6,952 4,873 2,079 1,068 711 357
Bladder 5,120 4,190 930 1,707 1,303 404
Brain and CNS 2,185 1,178 1,007 1,406 732 674
Thyroid 33,884 8,955 24,929 336 102 234
Hodgkin lymphoma 354 217 137 62 38 24
Non-Hodgkin lymphoma 6,038 3,477 2,561 2,314 1,325 989
Multiple myeloma 2,120 1,116 1,004 946 533 413
Leukemia 3,983 2,301 1,682 2,116 1,239 877
Other and ill defined 24,016 12,140 11,876 5,910 3,310 2,600

CNS, central nervous system.

a) Includes the liver and intrahepatic bile duct,

b) Includes the gallbladder and other/unspecified parts of the biliary tract,

c) Includes the lung and bronchus.

Table 2
Estimated crude and age-standardized cancer incidences by sex during 2022 in Korea
Site Crude incidence rates per 100,000 Age-standardized incidence rates per 100,000a)
Both sexes Men Women Both sexes Men Women
All sites 531.6 561.2 502.1 276.7 289.9 276.1
Lip, oral cavity, and pharynx 8.2 11.8 4.6 4.3 6.3 2.5
Esophagus 5.3 9.4 1.2 2.4 4.4 0.6
Stomach 51.2 68.3 34.1 24.0 34.0 15.3
Colon and rectum 56.5 66.8 46.3 26.4 33.8 19.8
Liverb) 28.1 41.9 14.3 12.9 20.9 5.7
Gallbladderc) 16.6 17.9 15.3 6.6 8.3 5.3
Pancreas 17.9 18.5 17.3 7.7 8.9 6.7
Larynx 2.1 3.9 0.2 0.9 1.8 0.1
Lungd) 64.5 84.8 44.3 27.6 39.4 18.6
Breast 54.5 0.4 108.3 33.1 0.2 66.1
Cervix uteri 5.8 - 11.5 3.7 - 7.4
Corpus uteri 7.1 - 14.1 4.2 - 8.3
Ovary 6.1 - 12.3 3.7 - 7.4
Prostate 43.4 87.0 - 18.4 40.3 -
Testis 0.7 1.3 - 0.7 1.3 -
Kidney 13.5 18.9 8.0 7.4 10.8 4.2
Bladder 9.9 16.3 3.6 4.1 7.6 1.3
Brain and CNS 4.2 4.6 3.9 3.0 3.4 2.7
Thyroid 65.6 34.8 96.3 47.6 24.8 71.2
Hodgkin lymphoma 0.7 0.8 0.5 0.6 0.7 0.5
Non-Hodgkin lymphoma 11.7 13.5 9.9 6.7 8.3 5.4
Multiple myeloma 4.1 4.3 3.9 1.8 2.1 1.6
Leukemia 7.7 8.9 6.5 5.7 6.7 4.6
Other and ill defined 46.5 47.2 45.9 23.2 25.9 20.9

CNS, central nervous system.

a) ge adjusted to the world standard population,

b) Includes the liver and intrahepatic bile duct,

c) Includes the gallbladder and other/unspecified parts of the biliary tract,

d) Includes the lung and bronchus.

Table 3
Estimated cancer incidence by age group and sex during 2022 in Korea
Rank Age group (yr)
0–14 15–34 35–64 ≥65
Men
 1 Leukemia (4.8) Thyroid (25.0) Colon and rectum (63.8) Prostate (453.6)
 2 Non-Hodgkin lymphoma (3.2) Leukemia (4.0) Stomach (63.2) Lunga) (423.1)
 3 Brain and CNS (2.3) Colon and rectum (3.8) Thyroid (51.0) Stomach (252.4)
 4 Kidney (0.3) Non-Hodgkin lymphoma (3.3) Lunga) (44.2) Colon and rectum (234.5)
 5 Liver (0.3) Testis (3.1) Liverb) (40.3) Liverb) (149.3)
Women
 1 Leukemia (4.0) Thyroid (75.1) Breast (179.0) Lunga) (145.5)
 2 Brain and CNS (2.1) Breast (12.8) Thyroid (146.4) Colon and rectum (143.2)
 3 Non-Hodgkin lymphoma (1.7) Cervix uteri (5.4) Colon and rectum (38.7) Breast (113.3)
 4 Ovary (0.8) Ovary (3.6) Lunga) (34.2) Stomach (100.4)
 5 Thyroid (0.6) Corpus uteri (3.0) Stomach (31.1) Pancreas (66.4)

CNS, central nervous system.

a) Includes the lung and bronchus,

b) Includes the liver and intrahepatic bile duct.

Table 4
Estimated crude and age-standardized cancer mortality rates by sex during 2022 in Korea
Site Crude mortality rates per 100,000 Age-standardized mortality rates per 100,000a)
Both sexes Men Women Both sexes Men Women
All sites 157.4 192.8 122.2 63.3 89.1 44.0
Lip, oral cavity, and pharynx 2.5 3.6 1.3 1.1 1.7 0.5
Esophagus 2.4 4.3 0.5 1.0 1.9 0.2
Stomach 10.5 13.9 7.2 4.1 6.5 2.2
Colon and rectum 17.0 18.9 15.1 6.6 8.8 4.7
Liverb) 18.5 27.2 9.9 7.7 13.0 3.2
Gallbladderc) 10.7 11.7 9.7 3.9 5.2 2.8
Pancreas 14.1 14.5 13.7 5.6 6.8 4.6
Larynx 0.4 0.8 0.0 0.2 0.4 0.0
Lungd) 35.5 52.9 18.2 13.4 23.4 5.9
Breast 5.6 0.1 11.2 2.9 0.0 5.7
Cervix uteri 1.5 - 2.9 0.7 - 1.4
Corpus uteri 0.8 - 1.6 0.4 - 0.8
Ovary 2.7 - 5.4 1.3 - 2.5
Prostate 4.4 8.9 - 1.4 3.8 -
Testis 0.0 0.1 - 0.0 0.1 -
Kidney 2.1 2.8 1.4 0.9 1.3 0.5
Bladder 3.3 5.1 1.6 1.1 2.2 0.4
Brain and CNS 2.7 2.8 2.6 1.5 1.7 1.4
Thyroid 0.7 0.4 0.9 0.2 0.2 0.3
Hodgkin lymphoma 0.1 0.2 0.1 0.1 0.1 0.0
Non-Hodgkin lymphoma 4.5 5.2 3.8 1.8 2.4 1.3
Multiple myeloma 1.8 2.1 1.6 0.7 0.9 0.5
Leukemia 4.1 4.8 3.4 1.9 2.5 1.5
Other and ill defined 11.4 12.9 10.0 4.8 6.3 3.5

CNS, central nervous system.

a) Age adjusted to the world standard population,

b) Includes the liver and intrahepatic bile duct,

c) Includes the gallbladder and other/unspecified parts of the biliary tract,

d) Includes the lung and bronchus.

  • 1. Statistics Korea [Internet]. Daejeon: Statistics Korea; 2022. [cited 2022 Mar 8]. Available from: http://kosis.kr
  • 2. Hong S, Won YJ, Lee JJ, Jung KW, Kong HJ, Im JS, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat. 2021;53:301–15. ArticlePubMedPMC
  • 3. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999–2001: first result using the National Cancer Incidence Database. Cancer Res Treat. 2005;37:325–31. ArticlePubMedPMC
  • 4. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed 1st rev. Geneva: World Health Organization; 2013.
  • 5. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. Geneva: World Health Organization; 1994.
  • 6. Boyle P, Parkin DM. Statistical methods for registries. . In: Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG, editors. Cancer registration: principles and methods. IARC Scientific Publication No 95Lyon: IARC Press; 1991. p. 126–58.
  • 7. National Cancer Institute. Joinpoint regression program, version 4.8.0.1 [Internet]. Bethesda, MD: National Cancer Institute; 2020. [cited 2022 Feb 18]. Available from: http://surveil-lance.cancer.gov/joinpoint/
  • 8. Segi M. Cancer mortality for selected sites in 24 countries 1950–1957. Sendai: Tohoku University School of Medicine; 1960.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Cucurbitacin-I exhibits anticancer activity by inducing apoptosis in SKOV3 human ovarian cancer cells
      Ji-Won Park, Seong Mi Kim, Soo Yeon Lee, Seung-Won Park, Jin-Kyung Kim
      Molecular & Cellular Toxicology.2025; 21(1): 271.     CrossRef
    • Docetaxel/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients With High-risk Endometrial Cancer After Staging Surgery: A Phase 2 Study
      Ok-Ju Kang, Yoon-Jung Cho, Myong Cheol Lim, Yeon Jee Lee, Sang Soo Seo, Sokbom Kang, Sang-Yoon Park, Young Seok Kim, Joo-Hyun Nam, Jeong-Yeol Park
      International Journal of Radiation Oncology*Biology*Physics.2025; 121(5): 1229.     CrossRef
    • LncRNA LINC01703 promotes the proliferation, migration, and invasion of colorectal cancer by activating PI3K/AKT pathway
      Yuanhui Xu, Keliang Jia, Xianhai Zhao, Yuantao Li, Zhen Zhang
      Journal of Biochemical and Molecular Toxicology.2024;[Epub]     CrossRef
    • MHY446 induces apoptosis via reactive oxygen species-mediated endoplasmic reticulum stress in HCT116 human colorectal cancer cells
      Yu Ra Ahn, Jung Yoon Jang, Yong Jung Kang, Hye Jin Oh, Min Kyung Kang, Dahye Yoon, Hyung Sik Kim, Hyung Ryong Moon, Hae Young Chung, Nam Deuk Kim
      Journal of Chemotherapy.2024; 36(6): 483.     CrossRef
    • Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea
      Da Som Jeon, Cheol‐kyu Park, Seung Joon Kim, Chan Kwon Park, Yoon Soo Chang, Chi Young Jung, Sung Yong Lee, Shin‐Yup Lee, Jeong‐Seon Ryu, Jeong Eun Lee, Kye Young Lee, Tae Won Jang, Seung Hun Jang, Seong Hoon Yoon, Sang Hoon Lee, Chang‐min Choi, Hyeong Ry
      Thoracic Cancer.2024; 15(6): 448.     CrossRef
    • Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
      Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo Sheen
      BMC Cancer.2024;[Epub]     CrossRef
    • Analysis of Breast Cancer Screening Results and Influencing Factors of Breast Cancer in Guangdong Province from 2017 to 2021
      Li Wu, Guo-Zhen Chen, Zu-Rui Zeng, Cun-Wei Ji, An-Qin Zhang, Jian-Hong Xia, Guo-Cheng Liu
      Journal of Epidemiology and Global Health.2024; 14(1): 131.     CrossRef
    • Peritoneal Washing Cytology Positivity in Gastric Cancer: Role of Lymph Node Metastasis as a Risk Factor
      Sojung Kim, Han Hong Lee, Kyo Young Song, Ho Seok Seo
      Journal of Gastric Cancer.2024; 24(2): 185.     CrossRef
    • The Short- and Long-Term Anticipation of Prostate Cancer Incidence in Korea: Based on Social Aging Trends and Prostate-Specific Antigen Testing Rate during the Last Decade
      Jong Hyun Pyun, Young Hwii Ko, Sang Won Kim, Nak-Hoon Son
      Cancers.2024; 16(3): 503.     CrossRef
    • Pretreatment Interstitial Lung Abnormalities Detected on Abdominal Computed Tomography Scans in Prostate Cancer Patients
      Hyun Jin Kim, Won Gi Jeong, Jeong Yeop Lee, Hyo-Jae Lee, Byung Chan Lee, Hyo Soon Lim, Yun-Hyeon Kim
      Journal of Computer Assisted Tomography.2024; 48(3): 406.     CrossRef
    • Combination of oxaliplatin and β-carotene suppresses colorectal cancer by regulating cell cycle, apoptosis, and cancer stemness in vitro
      Junghyeun Lee, Seung Chul Heo, Yuri Kim
      Nutrition Research and Practice.2024; 18(1): 62.     CrossRef
    • Association between Gout and Gastric Cancer: A Nested Case–Control Study Using a National Health Sample Cohort
      Mi Jung Kwon, Kyeong Min Han, Ji Hee Kim, Joo-Hee Kim, Min-Jeong Kim, Nan Young Kim, Hyo Geun Choi, Ho Suk Kang
      Journal of Personalized Medicine.2024; 14(3): 229.     CrossRef
    • Predictive value of SUVmax from initial 18F-FDG PET/CT scans for treatment outcomes in endometrial cancer patients undergoing fertility sparing management
      Ok-Ju Kang, Yonghee Park, Eun Min Lee, Jong Jin Lee, Shin-Wha Lee, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Jeong-Yeol Park
      International Journal of Gynecologic Cancer.2024; 34(8): 1189.     CrossRef
    • Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)
      Sung Hee Lim, Keun-Wook Lee, Jae-Joon Kim, Hyeon-Su Im, In-Ho Kim, Hye Sook Han, Dong-Hoe Koo, Jang Ho Cho, Chi Hoon Maeng, Min-Young Lee, Hyo Jin Lee, Jwa Hoon Kim, Sang Gon Park, Joo Young Jung, Seong-Hoon Shin, Ki Hyang Kim, Hyeyeong Kim, So Yeon Oh, M
      BMC Cancer.2024;[Epub]     CrossRef
    • Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study
      Gwan Hee Han, Hae-Rim Kim, Hee Yun, Jae-Hoon Kim, Hanbyoul Cho
      Targeted Oncology.2024; 19(2): 251.     CrossRef
    • Prostate-Specific Antigen-Based Prostate Cancer Screening: One for All or Individualized for Each Race? – A Narrative Review
      Chang Wook Jeong
      Journal of Urologic Oncology.2024; 22(1): 4.     CrossRef
    • The Expression and Amplification of HER2 Has a Significant Impact on the Prognosis of Endometrial Carcinoma in Korean Patients
      Wook Youn Kim, Eun Jung Yang, Eun Bi Jang, A Jin Lee, Kyeong A So, Seung-Hyuk Shim, Tae Jin Kim, Sun Joo Lee
      Journal of Clinical Medicine.2024; 13(8): 2158.     CrossRef
    • A survey of current practices in post-polypectomy surveillance in Korea
      Jeongseok Kim, Tae-Geun Gweon, Min Seob Kwak, Su Young Kim, Seong Jung Kim, Hyun Gun Kim, Eun Ran Kim, Sung Noh Hong, Eun Sun Kim, Chang Mo Moon, Dae Seong Myung, Dong Hoon Baek, Shin Ju Oh, Hyun Jung Lee, Ji Young Lee, Yunho Jung, Jaeyoung Chun, Dong-Hoo
      Intestinal Research.2024; 22(2): 186.     CrossRef
    • The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial
      Sung Hee Lim, Ashok Saluja, Selwyn Vickers, Jung Yong Hong, Seung Tae Kim, Shweta Lavania, Somnath Pandey, Vineet K. Gupta, Mohana R. Velagapudi, Jeeyun Lee
      Cancer Letters.2024; 597: 217041.     CrossRef
    • Lifestyle Behaviors in Patients With Gastric Cancer: Continuous Need for Alcohol Abstinence and Muscle Strength Training Education
      Ji Won Seo, Kyu Na Lee, Kyung Do Han, Ki Bum Park
      Journal of Gastric Cancer.2024; 24(3): 316.     CrossRef
    • Analysis of Aeromedical Consultation Related to Malignant Tumor of Korean Military Flight Crews
      Du Hyun Song
      The Korean Journal of Aerospace and Environmental Medicine.2024; 34(2): 40.     CrossRef
    • Natural Compounds for Preventing Age-Related Diseases and Cancers
      Mi-Ran Ki, Sol Youn, Dong Hyun Kim, Seung Pil Pack
      International Journal of Molecular Sciences.2024; 25(14): 7530.     CrossRef
    • Characterizing the Tumor Microenvironment and Its Correlation with cDC1‐Related Gene Expression in Gastric Cancer
      Song-Hee Han, Mi Ha Ju, Nitin Amdare
      Journal of Immunology Research.2024;[Epub]     CrossRef
    • Comparative analysis of machine learning and deep learning models for improved cancer detection: A comprehensive review of recent advancements in diagnostic techniques
      Hari Mohan Rai, Joon Yoo, Abdul Razaque
      Expert Systems with Applications.2024; 255: 124838.     CrossRef
    • Latent profile analysis for assessing symptom clusters in women with breast cancer
      Jin-Hee Park, Mison Chun, Sun Hyoung Bae, Jeonghee Woo, Eunae Chon, Hee Jun Kim
      Journal of Cancer Survivorship.2024;[Epub]     CrossRef
    • Modifiable risk factors for weight loss after cancer treatment in Korean gastric cancer survivors
      Junhee Park, Jiyoung Kim, Dong Wook Shin, Jinyoung Shin, BeLong Cho, Yun-Mi Song
      Journal of Cancer Survivorship.2024;[Epub]     CrossRef
    • Gochujang suppresses cell survival and changes reactive oxygen species metabolism in colorectal cancer cells
      Eun-Bi Seo, So-Min Oh, Anna Han
      Food & Nutrition Research.2024;[Epub]     CrossRef
    • Review of recent impacts of artificial intelligence for radiation therapy procedures
      Fouad Abdulaziz Abolaban
      Radiation Physics and Chemistry.2023; 202: 110469.     CrossRef
    • Valrubicin decreases cell proliferation in gastric cancer through the apoptosis induction
      Jang-Mi Bae, Won-Jin Kim, Woong Kim, Seok-Jun Kim
      Molecular & Cellular Toxicology.2023; 19(1): 155.     CrossRef
    • Incidence and survival rates of primary uterine carcinosarcoma in Korea: a National Cancer Registry study
      Se Ik Kim, Ji Hyun Kim, Cheol Lee, Johyun Ha, Kyu-Won Jung, Myong Cheol Lim
      Journal of Gynecologic Oncology.2023;[Epub]     CrossRef
    • Role of Adjuvant Radiotherapy in Gastric Cancer
      Jeong Il Yu
      Journal of Gastric Cancer.2023; 23(1): 194.     CrossRef
    • Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study
      Se Ik Kim, Hyunji Lim, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Maria Lee
      Cancer Research and Treatment.2023; 55(1): 245.     CrossRef
    • Therapeutic Potential of Bioactive Components from Scutellaria baicalensis Georgi in Inflammatory Bowel Disease and Colorectal Cancer: A Review
      Jung Yoon Jang, Eunok Im, Nam Deuk Kim
      International Journal of Molecular Sciences.2023; 24(3): 1954.     CrossRef
    • Venous Thromboembolism in Patients with Advanced Pancreatic Cancer Receiving Palliative Chemotherapy: Incidence and Effect on Prognosis
      Han Taek Jeong, June Hwa Bae, Ho Gak Kim, Jimin Han
      The Korean Journal of Gastroenterology.2023; 81(3): 109.     CrossRef
    • Understanding Heterogeneity in the Relationship Between Cancer and Hand Grip Strength: A Longitudinal Analysis
      Jinho Kim, Gum-Ryeong Park
      Research on Aging.2023; 45(7-8): 586.     CrossRef
    • Anastomotic leakage after resection of the rectosigmoid colon in primary ovarian cancer
      Ji Hyun Kim, Won Ho Han, Dong-Eun Lee, Sun Young Kim, Kiho You, Sung Sil Park, Dong Woon Lee, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park, Myong Cheol Lim
      Journal of Ovarian Research.2023;[Epub]     CrossRef
    • Interpretation of Rectal MRI after Neoadjuvant Treatment in Patients with Rectal Cancer
      Nieun Seo, Joon Seok Lim
      Journal of the Korean Society of Radiology.2023; 84(3): 550.     CrossRef
    • Vitamin E intake and paraoxonase 1 (PON1) rs662 genetic polymorphism are associated with colorectal cancer risk in a Korean population
      Quynh-Anh Bui, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
      International Journal of Food Sciences and Nutrition.2023; 74(4): 510.     CrossRef
    • New fungal protein from Pleurotus ferulae lanzi induces AMPK-mediated autophagy and G1-phase cell cycle arrest in A549 lung cancer cells
      Meng-Han Liu, Fang Liu, Tzi Bun Ng, Zhao-Kun Liu
      International Journal of Biological Macromolecules.2023; 244: 125453.     CrossRef
    • Association of immunotoxicological indices with lung cancer biomarkers in poultry, grape, and rose farming workers
      Anju Maharjan, Ravi Gautam, Manju Acharya, JiHun Jo, DaEun Lee, Pramod Bahadur K C, Young-A Lee, Jung-Taek Kwon, HyoCher Kim, KyungRan Kim, ChangYul Kim, HyoungAh Kim, Yong Heo
      Toxicological Research.2023; 39(4): 739.     CrossRef
    • Baseline Lower Urinary Tract Symptoms and Sexual Dysfunction in Men with Newly Diagnosed Localized Prostate Cancer
      Wan Song, Jun-Seop Kim, Kwang Jin Ko
      Journal of Clinical Medicine.2023; 12(13): 4462.     CrossRef
    • Urologic malignancies that cause hematuria
      Sung Jin Kim, Myungchan Park, Sangjun Yoo
      Journal of the Korean Medical Association.2023; 66(6): 363.     CrossRef
    • The Role of Magnetic Resonance Imaging (MRI) and MRI-Targeted Biopsy for Active Surveillance
      Chang Wook Jeong
      Journal of Urologic Oncology.2023; 21(2): 97.     CrossRef
    • Risk Factors and Prognosis of Stroke in Gynecologic Cancer Patients
      Ji Young Kwon, Kena Park, Jeong Min Song, Seung Yeon Pyeon, Seon Hwa Lee, Young Shin Chung, Jong-Min Lee
      Cancers.2023; 15(19): 4895.     CrossRef
    • Strategic planning for cancer control: Utilizing machine-learning models to predict future incidences
      Esraa Zeki Mohammed, Noor Ghazi M. Jameel, Ahmed Ibrahim Shukr, Ahmed Ghareeb
      Results in Control and Optimization.2023; 13: 100322.     CrossRef
    • The Role of Blood Microbiome in the Development of Thyroid Cancer in Breast Cancer Survivors
      Jeongshin An, Hyungju Kwon, Young Ju Kim
      Cancers.2023; 15(18): 4492.     CrossRef
    • Deciphering the DNA methylation landscape of colorectal cancer in a Korean cohort
      Seok-Byung Lim, Soobok Joe, Hyo-Ju Kim, Jong Lyul Lee, In Ja Park, Yong Sik Yoon, Chan Wook Kim, Jong-Hwan Kim, Sangok Kim, Jin-Young Lee, Hyeran Shim, Hoang Bao Khanh Chu, Sheehyun Cho, Jisun Kang, Si-Cho Kim, Hong Seok Lee, Young-Joon Kim, Seon-Young K
      BMB Reports.2023; 56(10): 569.     CrossRef
    • A Web-Based Decision Aid for Informed Prostate Cancer Screening: Development and Pilot Evaluation
      Wonyoung Jung, In Young Cho, Keun Hye Jeon, Yohwan Yeo, Jae Kwan Jun, Mina Suh, Ansuk Jeong, Jungkwon Lee, Dong Wook Shin
      Journal of Korean Medical Science.2023;[Epub]     CrossRef
    • Combined impact of myosteatosis and liver steatosis on prognosis in stage I–III colorectal cancer patients
      Dong Hee Lee, Il Jo, Hye Sun Lee, Jeonghyun Kang
      Journal of Cachexia, Sarcopenia and Muscle.2023; 14(6): 2908.     CrossRef
    • Endoscopic Resection of Early Gastric Cancer in Elderly
      Da Hyun Jung
      The Korean Journal of Gastroenterology.2022; 80(1): 1.     CrossRef
    • Stereotactic body radiation therapy for pancreatic cancer: a potential ally in the era of immunotherapy?
      Jin-hong Park
      Radiation Oncology Journal.2022; 40(3): 169.     CrossRef
    • Re-Increasing Trends in Thyroid Cancer Incidence after a Short Period of Decrease in Korea: Reigniting the Debate on Ultrasound Screening
      Chan Kwon Jung, Ja Seong Bae, Young Joo Park
      Endocrinology and Metabolism.2022; 37(5): 816.     CrossRef
    • Impact of modifiable reproductive factors on cancer incidence and mortality in Korea: a systematic review protocol
      Seo-Hee Kim, Mi Ah Han
      BMJ Open.2022; 12(11): e067826.     CrossRef
    • Omission of chemotherapy for hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: patterns of treatment and outcomes from the Korean Breast Cancer Society Registry
      Hannah Lois Kangleon-Tan, Jongmin Sim, Ji Young You, Eun-Shin Lee, Haemin Lee, Sun Moon Yang, Min-Ki Seong, Eun Hwa Park, Seok Jin Nam, Min Ho Park, Seokwon Lee, Woo-Chan Park, Rogelio G. Kangleon, Crisostomo B. Dy, Soo Youn Bae, Seung Pil Jung
      Annals of Surgical Treatment and Research.2022; 103(6): 313.     CrossRef
    • Trends in breast cancer screening rates among Korean women: results from the Korean National Cancer Screening Survey, 2005-2020
      Soo Yeon Song, Yun Yeong Lee, Hye Young Shin, Bomi Park, Mina Suh, Kui Son Choi, Jae Kwan Jun
      Epidemiology and Health.2022; 44: e2022111.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Prediction of Cancer Incidence and Mortality in Korea, 2022
      Cancer Res Treat. 2022;54(2):345-351.   Published online March 21, 2022
      DOI: https://doi.org/10.4143/crt.2022.179
      Close
    • XML DownloadXML Download
    • 0
    • 1
    • 2
    Prediction of Cancer Incidence and Mortality in Korea, 2022
    Image Image Image
    Fig. 1 The 10 leading types of estimated new cancer cases and deaths by sex in 2022. (A) Estimated new cases. (B) Estimated deaths.
    Fig. 2 Projected age-specific incidences of major cancers during 2022 in Korea. (A) Men. (B) Women.
    Fig. 3 Projected age-specific mortality rates of major cancers during 2022 in Korea. (A) Men. (B). Women.

    Fig. 1

    Fig. 2

    Fig. 3

    Prediction of Cancer Incidence and Mortality in Korea, 2022

    Estimated new cancer cases and deaths by sex during 2022 in Korea

    Site Estimated new cases Estimated deaths
    Both sexes Men Women Both sexes Men Women
    All sites 274,488 144,487 130,001 81,277 49,648 31,629
    Lip, oral cavity, and pharynx 4,212 3,024 1,188 1,270 922 348
    Esophagus 2,742 2,421 321 1,244 1,103 141
    Stomach 26,422 17,590 8,832 5,441 3,578 1,863
    Colon and rectum 29,165 17,187 11,978 8,790 4,873 3,917
    Livera) 14,493 10,782 3,711 9,549 6,994 2,555
    Gallbladderb) 8,558 4,606 3,952 5,540 3,017 2,523
    Pancreas 9,238 4,756 4,482 7,277 3,730 3,547
    Larynx 1,058 999 59 217 217 0
    Lungc) 33,294 21,837 11,457 18,320 13,606 4,714
    Breast 28,142 110 28,032 2,909 19 2,890
    Cervix uteri 2,971 - 2,971 749 - 749
    Corpus uteri 3,640 - 3,640 418 - 418
    Ovary 3,173 - 3,173 1,392 - 1,392
    Prostate 22,391 22,391 - 2,278 2,278 -
    Testis 337 337 - 18 18 -
    Kidney 6,952 4,873 2,079 1,068 711 357
    Bladder 5,120 4,190 930 1,707 1,303 404
    Brain and CNS 2,185 1,178 1,007 1,406 732 674
    Thyroid 33,884 8,955 24,929 336 102 234
    Hodgkin lymphoma 354 217 137 62 38 24
    Non-Hodgkin lymphoma 6,038 3,477 2,561 2,314 1,325 989
    Multiple myeloma 2,120 1,116 1,004 946 533 413
    Leukemia 3,983 2,301 1,682 2,116 1,239 877
    Other and ill defined 24,016 12,140 11,876 5,910 3,310 2,600

    CNS, central nervous system.

    a)Includes the liver and intrahepatic bile duct,

    b)Includes the gallbladder and other/unspecified parts of the biliary tract,

    c)Includes the lung and bronchus.

    Estimated crude and age-standardized cancer incidences by sex during 2022 in Korea

    Site Crude incidence rates per 100,000 Age-standardized incidence rates per 100,000a)
    Both sexes Men Women Both sexes Men Women
    All sites 531.6 561.2 502.1 276.7 289.9 276.1
    Lip, oral cavity, and pharynx 8.2 11.8 4.6 4.3 6.3 2.5
    Esophagus 5.3 9.4 1.2 2.4 4.4 0.6
    Stomach 51.2 68.3 34.1 24.0 34.0 15.3
    Colon and rectum 56.5 66.8 46.3 26.4 33.8 19.8
    Liverb) 28.1 41.9 14.3 12.9 20.9 5.7
    Gallbladderc) 16.6 17.9 15.3 6.6 8.3 5.3
    Pancreas 17.9 18.5 17.3 7.7 8.9 6.7
    Larynx 2.1 3.9 0.2 0.9 1.8 0.1
    Lungd) 64.5 84.8 44.3 27.6 39.4 18.6
    Breast 54.5 0.4 108.3 33.1 0.2 66.1
    Cervix uteri 5.8 - 11.5 3.7 - 7.4
    Corpus uteri 7.1 - 14.1 4.2 - 8.3
    Ovary 6.1 - 12.3 3.7 - 7.4
    Prostate 43.4 87.0 - 18.4 40.3 -
    Testis 0.7 1.3 - 0.7 1.3 -
    Kidney 13.5 18.9 8.0 7.4 10.8 4.2
    Bladder 9.9 16.3 3.6 4.1 7.6 1.3
    Brain and CNS 4.2 4.6 3.9 3.0 3.4 2.7
    Thyroid 65.6 34.8 96.3 47.6 24.8 71.2
    Hodgkin lymphoma 0.7 0.8 0.5 0.6 0.7 0.5
    Non-Hodgkin lymphoma 11.7 13.5 9.9 6.7 8.3 5.4
    Multiple myeloma 4.1 4.3 3.9 1.8 2.1 1.6
    Leukemia 7.7 8.9 6.5 5.7 6.7 4.6
    Other and ill defined 46.5 47.2 45.9 23.2 25.9 20.9

    CNS, central nervous system.

    a)ge adjusted to the world standard population,

    b)Includes the liver and intrahepatic bile duct,

    c)Includes the gallbladder and other/unspecified parts of the biliary tract,

    d)Includes the lung and bronchus.

    Estimated cancer incidence by age group and sex during 2022 in Korea

    Rank Age group (yr)
    0–14 15–34 35–64 ≥65
    Men
     1 Leukemia (4.8) Thyroid (25.0) Colon and rectum (63.8) Prostate (453.6)
     2 Non-Hodgkin lymphoma (3.2) Leukemia (4.0) Stomach (63.2) Lunga) (423.1)
     3 Brain and CNS (2.3) Colon and rectum (3.8) Thyroid (51.0) Stomach (252.4)
     4 Kidney (0.3) Non-Hodgkin lymphoma (3.3) Lunga) (44.2) Colon and rectum (234.5)
     5 Liver (0.3) Testis (3.1) Liverb) (40.3) Liverb) (149.3)
    Women
     1 Leukemia (4.0) Thyroid (75.1) Breast (179.0) Lunga) (145.5)
     2 Brain and CNS (2.1) Breast (12.8) Thyroid (146.4) Colon and rectum (143.2)
     3 Non-Hodgkin lymphoma (1.7) Cervix uteri (5.4) Colon and rectum (38.7) Breast (113.3)
     4 Ovary (0.8) Ovary (3.6) Lunga) (34.2) Stomach (100.4)
     5 Thyroid (0.6) Corpus uteri (3.0) Stomach (31.1) Pancreas (66.4)

    CNS, central nervous system.

    a)Includes the lung and bronchus,

    b)Includes the liver and intrahepatic bile duct.

    Estimated crude and age-standardized cancer mortality rates by sex during 2022 in Korea

    Site Crude mortality rates per 100,000 Age-standardized mortality rates per 100,000a)
    Both sexes Men Women Both sexes Men Women
    All sites 157.4 192.8 122.2 63.3 89.1 44.0
    Lip, oral cavity, and pharynx 2.5 3.6 1.3 1.1 1.7 0.5
    Esophagus 2.4 4.3 0.5 1.0 1.9 0.2
    Stomach 10.5 13.9 7.2 4.1 6.5 2.2
    Colon and rectum 17.0 18.9 15.1 6.6 8.8 4.7
    Liverb) 18.5 27.2 9.9 7.7 13.0 3.2
    Gallbladderc) 10.7 11.7 9.7 3.9 5.2 2.8
    Pancreas 14.1 14.5 13.7 5.6 6.8 4.6
    Larynx 0.4 0.8 0.0 0.2 0.4 0.0
    Lungd) 35.5 52.9 18.2 13.4 23.4 5.9
    Breast 5.6 0.1 11.2 2.9 0.0 5.7
    Cervix uteri 1.5 - 2.9 0.7 - 1.4
    Corpus uteri 0.8 - 1.6 0.4 - 0.8
    Ovary 2.7 - 5.4 1.3 - 2.5
    Prostate 4.4 8.9 - 1.4 3.8 -
    Testis 0.0 0.1 - 0.0 0.1 -
    Kidney 2.1 2.8 1.4 0.9 1.3 0.5
    Bladder 3.3 5.1 1.6 1.1 2.2 0.4
    Brain and CNS 2.7 2.8 2.6 1.5 1.7 1.4
    Thyroid 0.7 0.4 0.9 0.2 0.2 0.3
    Hodgkin lymphoma 0.1 0.2 0.1 0.1 0.1 0.0
    Non-Hodgkin lymphoma 4.5 5.2 3.8 1.8 2.4 1.3
    Multiple myeloma 1.8 2.1 1.6 0.7 0.9 0.5
    Leukemia 4.1 4.8 3.4 1.9 2.5 1.5
    Other and ill defined 11.4 12.9 10.0 4.8 6.3 3.5

    CNS, central nervous system.

    a)Age adjusted to the world standard population,

    b)Includes the liver and intrahepatic bile duct,

    c)Includes the gallbladder and other/unspecified parts of the biliary tract,

    d)Includes the lung and bronchus.
    Table 1 Estimated new cancer cases and deaths by sex during 2022 in Korea

    CNS, central nervous system.

    Includes the liver and intrahepatic bile duct,

    Includes the gallbladder and other/unspecified parts of the biliary tract,

    Includes the lung and bronchus.

    Table 2 Estimated crude and age-standardized cancer incidences by sex during 2022 in Korea

    CNS, central nervous system.

    ge adjusted to the world standard population,

    Includes the liver and intrahepatic bile duct,

    Includes the gallbladder and other/unspecified parts of the biliary tract,

    Includes the lung and bronchus.

    Table 3 Estimated cancer incidence by age group and sex during 2022 in Korea

    CNS, central nervous system.

    Includes the lung and bronchus,

    Includes the liver and intrahepatic bile duct.

    Table 4 Estimated crude and age-standardized cancer mortality rates by sex during 2022 in Korea

    CNS, central nervous system.

    Age adjusted to the world standard population,

    Includes the liver and intrahepatic bile duct,

    Includes the gallbladder and other/unspecified parts of the biliary tract,

    Includes the lung and bronchus.

    Table 1

    Table 2

    Table 3

    Table 4

    Cancer Res Treat : Cancer Research and Treatment
    © Korean Cancer Association.
    Close layer
    TOP